---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107727"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:42:38.844020+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint

## Summary
- Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.
- Oncology tests 211,000 (+53.9% YoY); record MRD sequential growth of ~21,500 units.
- Positive cash flow $26.4M in Q3; net loss $(0.64)/share vs $(0.26) YoY.
- Raises FY2025 revenue guidance to $2.18B-2.26B from $2.02B-2.10B.
- FY2025 guidance: gross margin ~62-64%; net cash inflow ~$100M.

## SEC filing metadata
- accession: 0001104659-25-107727
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465925107727/0001104659-25-107727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465925107727/tm2529763d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107727
- JSON: https://secwatch.observer/filing/0001104659-25-107727.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.